Evan Seigerman
Stock Analyst at BMO Capital
(3.80)
# 683
Out of 4,876 analysts
144
Total ratings
52.63%
Success rate
7.56%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Maintains: Outperform | $112 → $120 | $54.50 | +120.18% | 6 | May 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $96 → $115 | $125.42 | -8.31% | 15 | May 6, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $115 → $120 | $110.67 | +8.43% | 16 | Apr 17, 2025 | |
| BIIB Biogen | Maintains: Market Perform | $156 → $139 | $126.08 | +10.25% | 26 | Feb 13, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $520 → $545 | $441.30 | +23.50% | 15 | Jan 31, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $46.35 | +31.61% | 11 | Nov 12, 2024 | |
| INCY Incyte | Reiterates: Underperform | $48 → $52 | $68.37 | -23.94% | 12 | Oct 30, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,001 → $1,101 | $775.45 | +41.98% | 8 | Aug 9, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $21.08 | +89.75% | 1 | Feb 28, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $40 | $9.33 | +328.72% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $521.00 | +51.25% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $1.93 | +29.53% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $277.13 | -12.32% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $4.90 | +144.90% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $24.19 | +148.04% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $27 | $1.36 | +1,885.29% | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $1.19 | +2,421.01% | 3 | May 12, 2020 |
Disc Medicine
May 12, 2025
Maintains: Outperform
Price Target: $112 → $120
Current: $54.50
Upside: +120.18%
Neurocrine Biosciences
May 6, 2025
Maintains: Market Perform
Price Target: $96 → $115
Current: $125.42
Upside: -8.31%
Gilead Sciences
Apr 17, 2025
Maintains: Outperform
Price Target: $115 → $120
Current: $110.67
Upside: +8.43%
Biogen
Feb 13, 2025
Maintains: Market Perform
Price Target: $156 → $139
Current: $126.08
Upside: +10.25%
Vertex Pharmaceuticals
Jan 31, 2025
Maintains: Outperform
Price Target: $520 → $545
Current: $441.30
Upside: +23.50%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $46.35
Upside: +31.61%
Incyte
Oct 30, 2024
Reiterates: Underperform
Price Target: $48 → $52
Current: $68.37
Upside: -23.94%
Eli Lilly and Company
Aug 9, 2024
Maintains: Outperform
Price Target: $1,001 → $1,101
Current: $775.45
Upside: +41.98%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $21.08
Upside: +89.75%
Replimune Group
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $9.33
Upside: +328.72%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $521.00
Upside: +51.25%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $1.93
Upside: +29.53%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $277.13
Upside: -12.32%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $4.90
Upside: +144.90%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $24.19
Upside: +148.04%
Aug 13, 2021
Maintains: Outperform
Price Target: $30 → $27
Current: $1.36
Upside: +1,885.29%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $1.19
Upside: +2,421.01%